Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
May 13, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
May 06, 2021 07:30 ET | Source: Protara Therapeutics

Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End - - On Track to Complete TARA-002 GMP Scale up and Comparability in 2H, 2021 - - Plan to Engage with...
April 23, 2021 07:00 ET | Source: Protara Therapeutics

Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations

NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases...
April 19, 2021 16:09 ET | Source: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases...
April 19, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
March 11, 2021 07:30 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview

- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for...
March 10, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
February 04, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences

NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
February 02, 2021 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with...